Ensitrelvir is an antiviral agent specifically developed for treating COVID-19 caused by the SARS-CoV-2 virus, a type of RNA virus. It functions by inhibiting the 3CL protease (main protease), an enzyme critical for viral replication, thereby preventing the virus from effectively multiplying and spreading.

Administered as an oral medication, Ensitrelvir provides convenient and rapid treatment options for patients. Clinical studies have shown its efficacy in reducing the severity and duration of symptoms, as well as preventing hospitalization among high-risk individuals.

Furthermore, Ensitrelvir holds significant potential in managing viral outbreaks, helping to alleviate the strain on healthcare systems and enhance efforts to control disease transmission.